Abstract There is a lack of evidence regarding the optimal age at which to cease mammographic screening for breast cancer. This ecological study compared Australian state and territory level screening participation rates and cancer outcomes from 1996 to 2005 to identify the extent to which screening women aged 70-74 results in smaller, earlier stage breast cancers. With each 10 % absolute increase in screening participation, there was no significant difference in cancer incidence, but the incidence of large cancers was 8 % lower (IRR = 0.92, 95 % CI 0.90-0.94, p \ 0.001); there was some evidence of reduced nodal involvement at diagnosis (IRR 0.97, 95 % CI 0.95-0.99, p = 0.004) but this estimate was sensitive to assumptions regarding missing data. Increased mammographic screening of women aged 70-74 years reduces the incidence of large ([15 mm) cancers-and possibly cancers with nodal involvement-without a concomitant increase in overall cancer incidence.
Introduction
There is a lack of evidence regarding the optimal age at which to cease mammographic screening for breast cancer.
The International Association for Research in Cancer describes the current recommended upper age limit of 69 years as arbitrary [1] , and there is a lack of robust evidence about whether to screen women aged 70-74 years because trials did not include this age group in sufficient numbers [2] . This occurred for a number of reasons, including assumptions about competing mortality risks, the costs attached to screening and treatment versus years of life lost, reduction in quality of life associated with breast cancer diagnosis and treatment, and an expectation of lower participation by older women [1] . On the basis of the trial evidence, most screening programs have targeted women aged less than 70 years [3] . Thus, despite significant cancer incidence in this age group (in Australia, 30 cancer diagnoses per 10,000 women aged 70-74 compared to 35 in women aged 65-69 [4] ), it has not been possible to obtain evidence from observational studies to assess the potential benefits of extending the age range for screening.
The BreastScreen Australia program has since 1991 offered free, population-based biennial mammographic breast cancer screening to women from the age of 40 years [5] . Women aged 50-69 years are targeted for screening through mailed invitation upon reaching 50 years of age (via electoral roll registrations, which include over 95 % of the eligible population [6] ), mailed re-invitation to repeat screens, and media campaigns directed at this age group [7] . The target age range was recently extended to 74 years [8] . Between 1996 and 2005 there was substantial variation in participation by women aged 70-74 years because some state and territory BreastScreen services elected to invite them to subsequent-round screening by mail. For example, in 2004-2005, despite similar participation rates by women aged 65-69 years in all states and territories, participation by women aged 70-74 years averaged 52 % in jurisdictions where they were re-invited to subsequent screening rounds by mail, and 24 % where they were not [9] ( Table 1) .
This variation in screening participation provided a 'natural experiment' from which the effectiveness of screening women aged 70-74 years can be evaluated. Since screening aims to detect breast cancers earlier, cancers diagnosed in states and territories with higher rates of screening participation should tend to be smaller, with less nodal involvement; this is important in Australia where women in their seventies have poorer survival if their cancers are large or node-positive [10] . Breast cancer incidence would not necessarily be higher in women aged 70-74 with increased screening, because nearly all (approximately 99 %) of BreastScreen participants aged 70-79 years have been screened some time previously [11] and 70 % have been screened within the previous 27 months [12] , avoiding any significant short-term peak in incidence expected with prevalent-round screening.
This ecological study used Australian screening and cancer registry data from 1996 to 2005 to assess whether screening participation was associated with state-level incidence of invasive cancers; a decline in large ([15 mm) breast cancers; and a reduction in cancers with nodal involvement.
Methods

Data collection
BreastScreen participation data (the number of women screened and female population figures) was collected according to state/territory, 5-year age group and 2-year calendar period for the years 1996-2005 from annual BreastScreen Australia Monitoring Reports [9, [13] [14] [15] [16] [17] .
Data on cancer incidence, size and nodal involvement was requested from all state and territory cancer registries, by 5-year age group and year, for the period 1996-2005. We excluded the Northern Territory because there was not a sufficient number of cancers due to the small population. Cancer incidence data (8,743 cancers in total) were obtained from all approached state and territory cancer registries except South Australia. Only some registries routinely collected data on size and nodal status [7] ; information on both was provided by New South Wales (1997), Queensland (1996 Queensland ( -2004 , Tasmania (1996 Tasmania ( -2004 ), Victoria (1996 Victoria ( -2004 and Western Australia (1996) (1997) (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) . The Australian Capital Territory did not collect this information for any year. Because there was missing data on size and nodal status, we conducted a range of sensitivity analyses to evaluate the potential bias that might arise due to these missing data. Screening participation is also shown for women aged 65-69 years, who were consistently re-invited to screening in all jurisdictions during this period Analysis For all analyses, calendar time was aggregated into 2-year periods because screening participation was reported only by 2-year period.
Screening participation and breast cancer incidence
To assess the association between screening participation and invasive breast cancer incidence, a Poisson model was fitted for states and territories with available data on size and nodal status; the predictor term was screening participation, the outcome was the number of cancers diagnosed. Screening participation was fitted as a proportion divided by ten; this meant that the effect size indicated the proportional change in cancer incidence with each 10 % absolute increase in screening participation. The female population aged 70-74 years was fitted as the model weight. The model accounted for clustering by state/territory. Where only single years of cancer data were available, outcomes were compared to screening participation for the 2-year period including that year. We tested whether calendar time (2-year calendar period fitted as a linear term) was statistically significant (p \ 0.05); it was not, so it was excluded from final models.
The same regression model structure was used to examine the incidence of large cancers and cancers with nodal involvement. To account for missing information on tumour size and nodal involvement within units of analysis (state/territory and 2-year period), each analysis unit's population size was weighted according to the proportion of cancers for which the tumour characteristic was known. For example, if for some 2-year period and state/territory tumour size was recorded for 70 % of all invasive cancers at the cancer registry, the fitted population for that 2-year period and state/territory was scaled to 70 % of the observed population size. This ensured that the observed rates of small cancers were fitted while statistically powering the Poisson model only to the actual number of cancers for which the outcome of interest was known.
Sensitivity analyses
For states/territories and calendar periods with some available size or nodal status information, several assumptions about missing information were tested to assess the possible effects of bias due to missing data. For tumour size we tested two extreme assumptions:
1. All cancers missing tumour size information were large ([15 mm).
2. All cancers missing tumour size information were small (B15 mm).
Similarly, for nodal status we tested the assumptions:
1. All cancers missing information on nodal status had nodal involvement. 2. All cancers missing information on nodal status had no nodal involvement.
Models of these assumptions were weighted to ensure suitable statistical power (refer to Supplemental Materials for detailed methods).
The primary analysis was restricted to states/territories and years for which tumour size and nodal involvement was known (the 'restricted dataset').
It is possible that the associations between screening participation rates and the incidence of large and nodepositive cancers were different for the states and territories that collected this information. To assess whether this was likely, we compared the association between participation and cancer incidence using the restricted dataset to the association found for all years and states/territories for which breast cancer incidence was known (the 'full dataset'). We reasoned that if these associations were similar, findings on the association between participation and tumour size/nodal involvement could be generalised to the total population of Australian women aged 70-74 during this time period.
Analyses were conducted using Stata 11.0 (StataCorp., College Station, TX). This study was approved by the BreastScreen Victoria Research and Evaluation Committee in 2007.
Results
Screening participation and breast cancer incidence
The restricted dataset included a total of 5,437 cancers. Of these, 2,323 (43 %) were recorded as large, 2,424 (45 %) as small and 720 (13 %) were missing information on tumour size. In terms of nodal involvement, 1,351 (25 %) were recorded as node-positive, 2,730 (50 %) as nodenegative and 1,356 (25 %) were missing information on nodal involvement. Two-yearly cancer incidence by state/ territory ranged from 22 to 38 per 10,000 women, and screening participation ranged from 15 to 53 %. Detailed figures for the most recent period are shown in Table 1 . More detailed data can be obtained from the authors on request.
There was no evidence that invasive breast cancer incidence was associated with participation (IRR = 1.01, 95 % CI 0.99-1.03; Table 2 )-a finding consistent with minimal overdiagnosis (screen-detection of cancers that would never present clinically). This result was the same using the full dataset (8,743 cancers) to assess generalisability (IRR = 1.01, 95 % CI 1.00-1.02, p = 0.156).
Population-level incidence of large cancers among women aged 70-74 years was on average 8 % lower with each 10 % absolute increase in screening participation (IRR = 0.92, 95 % CI 0.90-0.94, p \ 0.001). Since we use a log-linear regression model this means, for example, if participation increased from 50 to 60 %, the population incidence of large breast cancers would be expected to reduce by a proportion of 8 % (IRR = 0.92), and if participation increased from 50 to 70 %, the population incidence of large breast cancers would be expected to reduce by a proportion of 15 % (IRR = 0.92 2 = 0.85). The association was similar if all cancers missing information on size were assumed to be small or, alternatively, assumed to be large (Table 2) .
Screening participation was associated with a 3 % proportional reduction in the incidence of cancers with nodal involvement with each 10 % absolute increase in screening participation (IRR = 0.97 (0.95-0.99), p = 0.004). This means, for example, if participation increased from 50 to 60 %, 3 % fewer women would be expected to have positive axillary lymph nodes (IRR = 0.97), and if participation increased from 50 to 70 %, 6 % fewer women would be expected to have positive axillary lymph nodes (IRR = 0.97 2 = 0.94). Sensitivity analyses indicated that this effect size would increase slightly (to IRR = 0.95 with each 10 % increase in participation) if all cancers missing information on nodal status were assumed to have nodal involvement; however, there was no evidence of a reduction if we assumed that all cancers missing information on nodal status had no nodal involvement (Table 2 ).
Discussion
This study shows that in the Australian population-based mammographic screening program, higher screening participation by women aged 70-74 years was associated with a higher incidence of cancers with a better prognosis (smaller and node-negative cancers) without a concomitant rise in overall breast cancer incidence. With a 10 % absolute increase in screening participation, it is estimated that 8 % fewer women would be diagnosed with large cancers. There is some evidence that fewer women (around 3 %) would be expected to have positive axillary lymph nodes, but this estimate was sensitive to assumptions regarding missing data.
A strength of this study is that it utilised a 'natural experiment' in a large population with a well-organised population breast cancer screening program and goodquality information on screening participation and cancer incidence.
As a limitation, this ecological study relied on population-level data, with no individual-level information on screening participation or cancer outcomes. Therefore, we were unable to estimate cancer outcomes for screened versus unscreened women. An observational study such as a cohort study would generate this important evidence.
The finding of fewer large cancers with increased participation was robust to different assumptions about missing data. However, it is likely that in our primary analysis we overestimated the association between screening participation and node-positive cancers; our sensitivity analysis where we assumed that all cancers missing nodal information were non-nodal is most likely closer to the truth, because nodal information would be missing when surgeons did not sample the nodes on the basis that nodal involvement was unlikely. As expected, we observed no increase in population cancer incidence with increased participation; screening in this age group appears to advance cancer detection predominantly through earlier detection of incident cancers.
The known poorer survival for Australian women aged 70-74 years with larger cancers at diagnosis suggests that the effects of screening observed in this study would lead [18] . While the Swedish Two County Trial showed no significant mortality reduction for women aged 70-74 years on entry [19] , it is difficult to compare these results to a population program like BreastScreen Australia because women in the trial were offered only two screens in total and they had not been invited to screening prior to age 70 years. It will be useful in the future to review mortality outcomes following the recent extension of the BreastScreen Australia target age range to 74 years. Any benefits of screening need to be balanced against potential negative consequences. For example, overdiagnosis needs to be minimised; this study found that higher screening participation by women aged 70-74 years was not associated with a rise in population-level cancer incidence, suggesting that overdiagnosis is minimal in this age group. False positive screening tests (screening mammograms with a positive result, where the screening client is cleared of cancer after further assessment such as further imaging and biopsies) should also be minimised, but they are less likely in this age group than the current target age range: while 10 % of positive screening tests result in a cancer diagnosis for women aged 50-69 years, the figure for women aged 70-79 years is 18 % [9] ). Other potential negative consequences of screening participation include loss of quality of life through earlier cancer diagnosis and treatment, which is increasingly important in developed countries such as Australia where life expectancy is increasing.
A randomised controlled trial of screening in women aged 70-74 years would produce the highest quality evidence regarding screening effectiveness. Such a trial could include assessments of cost-effectiveness and quality of life. In the absence of trial data, further observational studies from countries with organised screening programs are needed. In particular, given problems with the recording of nodal status, further analyses of data from programs with more complete information on nodal status would add considerably to the evidence base.
In conclusion, increased screening participation by women aged 70-74 years is associated with reduced tumour size and possibly reduced nodal involvement at diagnosis without a concomitant increase in cancer incidence. This suggests that extension of age-targetted screening to this age group-as recently done by BreastScreen Australia-is beneficial and can be done without a concern of increased overdiagnosis.
